20240025963. DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES simplified abstract (2seventy bio, Inc.)

From WikiPatents
Jump to navigation Jump to search

DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES

Organization Name

2seventy bio, Inc.

Inventor(s)

JORDAN Jarjour of SEATTLE WA (US)

WAI-HANG Leung of SEATTLE WA (US)

DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240025963 titled 'DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES

Simplified Explanation

The present disclosure describes improved compositions for adoptive T cell therapies targeting EGFR or EGFRvIII for the treatment, prevention, or alleviation of symptoms associated with cancer, infectious diseases, autoimmune diseases, inflammatory diseases, immunodeficiency, or related conditions. The disclosure also relates to adoptive T cell therapies targeting EGFR or EGFRvIII in combination with another target antigen for the same purposes.

  • The patent application focuses on improved compositions for adoptive T cell therapies.
  • The therapies target EGFR or EGFRvIII, which are proteins associated with various diseases.
  • The purpose of the therapies is to treat, prevent, or alleviate symptoms of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, immunodeficiency, or related conditions.
  • The disclosure also includes combinations of adoptive T cell therapies targeting EGFR or EGFRvIII with another target antigen.
  • The patent application aims to provide a more effective approach to treating these diseases by targeting specific antigens.

Potential Applications:

  • Treatment of various types of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, immunodeficiency, or related conditions.
  • Prevention of the development or progression of these diseases.
  • Alleviation of symptoms associated with these diseases.

Problems Solved:

  • Lack of effective treatments for certain types of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, immunodeficiency, or related conditions.
  • Inadequate targeting of specific antigens associated with these diseases.
  • Limited options for adoptive T cell therapies.

Benefits:

  • Improved efficacy in treating, preventing, or alleviating symptoms of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, immunodeficiency, or related conditions.
  • Enhanced targeting of specific antigens, leading to more precise and effective therapies.
  • Potential for combination therapies to address multiple target antigens simultaneously.


Original Abstract Submitted

the present disclosure provides improved compositions for adoptive t cell therapies targeting egfr or egrfviii for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. the present disclosure also relates to adoptive t cell therapies targeting egfr or egrfviii and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Retrieved from "http://wikipatents.org/index.php?title=20240025963._DIMERIZING_AGENT_REGULATED_IMMUNORECEPTOR_COMPLEXES_simplified_abstract_(2seventy_bio,_Inc.)&oldid=29574"